The invention relates to the use of a composition comprising at least one mixture of molecules obtained from Vitis vinifera and Vaccinium angustifolium, said mixture comprising: at least 1% of catechins and/or epicatechins, the percentage being given by weight relative to the total weight of the mixture, at least 5 ppm (parts per million in the mixture) of ferulic acid, and at least 200 ppm of resveratrol,
as a single dose in a healthy human being or animal to improve or maintain cognitive functions.

The invention relates to the use of a composition comprising at least one mixture of molecules obtained from Vitis vinifera and Vaccinium angustifolium, said mixture comprising: at least 1% of catechins and/or epicatechins, the percentage being given by weight relative to the total weight of the mixture, at least 5 ppm (parts per million in the mixture) of ferulic acid, and at least 200 ppm of resveratrol,
as a single dose in a healthy human being or animal to improve or maintain cognitive functions.

The oral supplements of the present invention utilize phenolic compounds in combination with creatine, choline, and trisodium citrate, wherein when taken together result in enhanced cellular permeation in comparison to cellular permeation in the absence of the other compounds of the combination leading to improved brain and/or physical functioning.

The oral supplements of the present invention utilize phenolic compounds in combination with creatine, choline, and trisodium citrate, wherein when taken together result in enhanced cellular permeation in comparison to cellular permeation in the absence of the other compounds of the combination leading to improved brain and/or physical functioning.

The present invention relates to a composition for preventing or treating Parkinson's disease comprising AEG-1 (S298D) as an active ingredient, and in the present invention, a point mutation was introduced into AEG-1 to induce a constitutively active form of AEG-1 (S298D), to construct AAV-AEG-1 (S298D), and to apply an animal model for Parkinson's disease, and accordingly, it was confirmed that it exhibits a protective effect on brain tissue by preserving dopaminergic neurons and dopamine nerve fibers and thus AEG-1 is useful as a composition for preventing or treating Parkinson's disease, a health food composition for preventing or improving Parkinson's disease, etc.

The present invention relates to a composition for preventing or treating Parkinson's disease comprising AEG-1 (S298D) as an active ingredient, and in the present invention, a point mutation was introduced into AEG-1 to induce a constitutively active form of AEG-1 (S298D), to construct AAV-AEG-1 (S298D), and to apply an animal model for Parkinson's disease, and accordingly, it was confirmed that it exhibits a protective effect on brain tissue by preserving dopaminergic neurons and dopamine nerve fibers and thus AEG-1 is useful as a composition for preventing or treating Parkinson's disease, a health food composition for preventing or improving Parkinson's disease, etc.

Methods and compositions for relieving general and chronic fatigue, restoring energy, rejuvenating sore muscles, and relieving associated pain by administering a composition including caffeine, and a Cannabis component having one or more compounds. An aqueous composition (e.g., an “energy” drink) comprises the caffeine and a Cannabis component selected from the group of cannabidiol (CBD), tetrahydrocannabinol (THC), hemp oil, Cannabis oil, and CBD together with THC. They are dissolved or diluted in water along with optional GRAS ingredients.

Methods and compositions for relieving general and chronic fatigue, restoring energy, rejuvenating sore muscles, and relieving associated pain by administering a composition including caffeine, and a Cannabis component having one or more compounds. An aqueous composition (e.g., an “energy” drink) comprises the caffeine and a Cannabis component selected from the group of cannabidiol (CBD), tetrahydrocannabinol (THC), hemp oil, Cannabis oil, and CBD together with THC. They are dissolved or diluted in water along with optional GRAS ingredients.

Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75% in combination with at least one of a monoglyceride, a free fatty acid, a salt of a free fatty acid, a phospholipid, and cholesterol.

Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75% in combination with at least one of a monoglyceride, a free fatty acid, a salt of a free fatty acid, a phospholipid, and cholesterol.